Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) EBITDA (2016 - 2020)

Historic EBITDA for Forte Biosciences (FBRX) over the last 5 years, with Q1 2020 value amounting to -$10.3 million.

  • Forte Biosciences' EBITDA rose 3962.33% to -$10.3 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$56.7 million, marking a year-over-year decrease of 697.11%. This contributed to the annual value of -$63.5 million for FY2019, which is 2970.54% down from last year.
  • Per Forte Biosciences' latest filing, its EBITDA stood at -$10.3 million for Q1 2020, which was up 3962.33% from -$10.6 million recorded in Q4 2019.
  • Over the past 5 years, Forte Biosciences' EBITDA peaked at -$352000.0 during Q3 2018, and registered a low of -$19.6 million during Q4 2018.
  • For the 5-year period, Forte Biosciences' EBITDA averaged around -$11.5 million, with its median value being -$10.3 million (2020).
  • In the last 5 years, Forte Biosciences' EBITDA skyrocketed by 9646.2% in 2018 and then plummeted by 522613.64% in 2019.
  • Over the past 5 years, Forte Biosciences' EBITDA (Quarter) stood at -$8.4 million in 2016, then fell by 28.78% to -$10.9 million in 2017, then crashed by 80.37% to -$19.6 million in 2018, then skyrocketed by 45.85% to -$10.6 million in 2019, then rose by 3.07% to -$10.3 million in 2020.
  • Its EBITDA stands at -$10.3 million for Q1 2020, versus -$10.6 million for Q4 2019 and -$18.7 million for Q3 2019.